Could Cetuximab Maintenance Play a Role in RAS Wild-Type Metastatic CRC?
Maintenance therapy with cetuximab (Erbitux) after FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus cetuximab induction therapy led to better outcomes for patients with RAS wild-type metastatic colorectal cancer (CRC) in a phase II randomized trial, yet it failed to reach the study’s prespecified threshold for success. At 6 months after randomization, more patients assigned to maintenance […]